Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Workday
WDAY
5
Lantheus
LNTH
US OptionsDetailed Quotes
STOK250516P10000
- 0.80
- 0.000.00%
15min DelayClose Apr 30 16:00 ET
0.00High0.00Low
0.80Open0.80Pre Close0 Volume6 Open Interest10.00Strike Price0.00Turnover83.98%IV5.74%PremiumMay 16, 2025Expiry Date0.24Intrinsic Value100Multiplier15DDays to Expiry0.56Extrinsic Value100Contract SizeAmericanOptions Type-0.5177Delta0.2359Gamma12.20Leverage Ratio-0.0214Theta-0.0023Rho-6.32Eff Leverage0.0080Vega
Stoke Therapeutics Newsroom
Stoke Therapeutics Analyst Ratings
Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $22
CCORF Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $20
Stoke Therapeutics Remains Significantly Undervalued, Says Canaccord
Chardan Capital Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $24
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $47
Analysts Offer Insights on Healthcare Companies: Intensity Therapeutics, Inc. (INTS) and Stoke Therapeutics (STOK)
Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $22
TD Cowen Maintains Stoke Therapeutics(STOK.US) With Buy Rating
Stoke Therapeutics Analyst Ratings
Positive Outlook for Stoke Therapeutics: Buy Rating Backed by Strong Leadership Transition, Robust Financial Position, and Promising Phase 3 Trial
Analysts Conflicted on These Healthcare Names: Halozyme (HALO), Stoke Therapeutics (STOK) and Lantheus (LNTH)
A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $22 to $47
Stoke Therapeutics Price Target Raised to $47.00/Share From $35.00 by HC Wainwright & Co.
Stoke Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Stoke Therapeutics Analyst Ratings
Strategic Collaboration and Positive Clinical Data Propel Stoke Therapeutics to a Buy Rating
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35
Stoke Therapeutics' Promising Potential: Buy Rating Backed by Strong Phase 3 Trial Design and Positive Early Results
Stoke Therapeutics Analyst Ratings
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
